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Abstract
Artemisinin and its derivatives are highly effective antimalarial drugs. These 
compounds combine potent and rapid antimalarial activity with a wide therapeutic 
index. An initiation of artemisinin resistance, described by a delayed parasite 
clearance time, is unlikely to cause high-level resistance. Artemisinins as a class 
demonstrate poor efficacy as monotherapy. This shortcoming can be overcome 
using oral artemisinin-based combination therapies (ACT) and intravenous-arte-
sunate (IV-AS) in combination with slow-acting partner drugs. Pharmacokinetic 
and pharmacodynamic (PK/PD) evaluation demonstrates that the rapid efficacy 
of artemisinins is largely due to drug peak concentrations. Critical evaluation also 
demonstrates that AS is superior in PK/PD either following oral or intravenous 
administration when compared to the other rapid-acting artemisinins. This rapid 
efficacy and decreased mortality demonstrates that currently available artemisi-
nins have a great advantage when combined with slow-acting antimalarial drugs 
for uncomplicated malaria or in sequential therapy with AS injection initially for 
severe and complicated malaria. Compared to other ACTs, dihydroartemisinin-
piperaquine (DP) demonstrates a superior in PK/PD profile, most likely due to the 
long half-life of piperaquine. These findings will help us better understand the PK/
PD profiles of rapid-acting (artemisinins) and slow-acting (piperaquine) drugs, 
and suggest how to best use ACTs in the future.
Keywords: artemisinin, artesunate, piperaquine, pharmacokinetics, 
pharmacodynamics
1. Introduction
The artemisinin group of antimalarials is considered to be highly and rapidly 
effective compared with other traditional malaria drugs. Resistance to artemisinins 
emerged in 2008 in parts of Southeast Asia and continues to spread [1]. Although 
there is more evidence to confirm drug resistance [2, 3], artemisinin and its deriva-
tives are still widely used in current malaria therapy [2, 4]. Clinical artemisinin 
resistance is demonstrated as a delayed clearance phenotype; that is, infection 
finally resolves with treatment with artemisinin-based combination therapies 
(ACTs), but the time required for parasite clearance substantially increases [5].
Malaria
2
High rates of recrudescence with daily monotherapy of artemisinins for 3–5 days 
are observed in humans. However, this shortfall is being overcome using oral ACTs 
and injectable artesunate (IV-AS) in combination with slow-acting antimalarial 
drugs. The rapid parasite killing of artemisinins in the treatment of early uncom-
plicated malaria with ACTs may prevent its progression to more severe disease 
with subsequent reduction in severe cases and associated mortality [6]. ACTs are 
currently the preferred treatment for malaria due to their enhanced efficacy and the 
potential to lower the emergence and spread of resistance [7].
The WHO has endorsed ACTs as the “policy standard” for all malaria infec-
tions in areas where P. falciparum is the predominant infecting species. Four ACTs 
recommended by a WHO Expert Consultative Group in 2001 are artemether 
(AM)-lumefantrine (Coartem), AS-mefloquine (Artequin), AS-amodiaquine, and 
AS-sulfadoxine/pyrimethamine [8]. Monotherapy with the artemisinins was signifi-
cantly decreased after 2001 to prevent the emergence of resistance. However, IV-AS, 
as a monotherapy, is still in first line of treatment for both adults and children in Asian 
countries [9] for complicated and severe malaria, as well as some areas in Africa [10].
Recent trials have used IV-AS with its more favorable pharmacokinetic profile 
[11, 12]. The SEAQUAMAT trial, a large multicenter randomized trial carried out in 
Bangladesh, Thailand, Myanmar, Indonesia, India, and Vietnam, showed a 34.7% 
reduction in mortality from all causes associated with IV-AS as compared to intrave-
nous quinine [13]. This remains the largest trial performed for severe malaria and was 
the first to conclusively demonstrate a benefit over standard quinine therapy. There is 
strong evidence that IV-AS will reduce the risk of death by one-third when compared 
to quinine therapy in cases of severe malaria. Consequently, IV-AS was immedi-
ately recommended for patients with severe malaria by The European Network on 
Imported Infections Disease Surveillance (TropNetEurop) after these trials [14].
The most recent development in antimalarial therapy is the use of artemisinin 
derivatives, especially IV-AS, which will potentially revolutionize the management 
of severe and complicated [15]. Therefore, there is a strong case for continued need 
for AS as a monotherapy, if only for this niche indication [16]. However, there is 
currently no useable formulation available that is produced under good manufac-
turing practice (GMP) conditions. The Walter Reed Army Institute of Research 
(WRAIR) continues to develop a novel cGMP injection of AS since 2004, which is 
in the process of US FDA approval [17, 18].
2. PK/PD evaluation of the artemisinins in patients
Pharmacokinetics (PK), in general, comprises three distinct phases (absorption, 
distribution, and elimination) of artemisinin drugs in blood after oral, intravenous, 
or intramuscular administration. Following single oral administration, AS and 
dihydroartemisinin (DHA) have short mean residence times (MRT) of 2.0 and 
2.7 h, respectively, and artemisinin (QHS) has a longer MRT of 7.4 h. Following 
intramuscular injections, arteether (AE) and AM both display very long MRTs at 
13.9 and 42.9 h respectively. However, IV-AS displays the shortest MRT (0.90 h) 
after intravenous injection (Table 1). It is obvious that the different artemisinins 
and the method of their delivery result in significant differences in PK charac-
teristics in humans. After multiple administrations, four drug concentrations of 
QHS, DHA, AS, and AM have been reported to decline daily due to autoinduction 
metabolism [19–23] that may result in the high rates of recrudescence with the 
monotherapy at a multiple dosing.
Pharmacodynamics (PD) has similarities to PK profiles but instead measures 
parameters of efficacy. For any antimalarial, the mean parasitemia-time curve 
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PK/PD parameters AS [25–27] AS [22, 28, 29] DHA [30–32] QHS [33, 34] AM [35–37] AE [37–39]
Route of administration Intravenous Oral Oral Oral Intramuscular Intramuscular
First loading dosage 120 mg 100 mg 200 mg 500 mg 3.2 mg/kg 4.8 mg/kg
Maintaining dosage Oral 100 mg at 8 h 50 mg b.i.d. × 4 100 mg × 4 250 × 2 × 5 1.6 mg/kg × 4 1.6 mg/kg × 5
Total dose 220 mg and mefloquine** 500 mg 600 mg 3000 mg 9.6 mg/kg 12.8 mg/kg
PK parameters (day 1)
Cmax (ng/ml) 2646 (DHA); 11,343(AS) 1052 (DHA); 198 (AS) 437.5 588.0 74.9 110.1
Tmax (h) 0.13 0.75 1.4 2.4 6.0 8.2
Tlag (h) 0.2 0.45
AUC0–24 h (ng h/ml) 2378 (DHA); 1146 (AS) 1334 (DHA); 210 (AS) 1329 2601 1230 4702
t1/2 (absorption, h) — 0.36 (DHA) 0.67 1.21 1.88 3.2
t1/2 (elimination, h) 0.67 (DHA); 0.05 (AS) 0.70 (DHA) 0.85 2.3 7.83 22.7
MRT (h) 0.90 (DHA) 1.95 (DHA) 2.71 7.41 13.94 42.9
PD parameters (day 1)*
Time of lag phase (h) 1.92 2.81 4.03 5.76 7.26 8.89
AUIC (% h/μl) 397.3 921.2 1167.9 1464.4 1613.4 2463.5
PC50 (h) 3.18 8.48 10.05 13.95 15.63 19.68
Emax (%) or MPC 0.0011 0.0016 0.2132 0.0100 0.0030 0.5504
Curative rate (%) 100** 81.3 76.0 74.3 86.7 48.0
*The data was fitted with WinNonlin (V5.0) by author.
**Oral 750 mg mefloquine at 24 h after IV injection. PK = pharmacokinetics; PD = pharmacodynamics; MRT = mean residence time; PC50 = mean time for parasitemia to fall by half; AUIC = area under 
inhibitory curve; QHS = artemisinin; DHA = dihydroartemisinin; AM = artemether; AE = arteether; AS = artesunic acid; MPC = minimum parasiticidal concentration; IM = intramuscular.
Table 1. 
Pharmacokinetics/pharmacodynamics (PK/PD) parameters of IV-AS (IV 120 mg and oral 100 mg at 8 h, then oral 750 mg mefloquine at 24 h), AS (oral, 100 mg and then 50 mg b.i.d × 4), DHA 
(oral, 200 mg and then 100 mg × 4), QHS (oral, 500 mg and 250 b.i.d × 4 and then 500 mg on D6), AM (IM, 3.2 mg/kg and 1.6 mg × 4), and AE (IM, 4.8 mg/kg at 0 h and 1.6 mg/kg at 6 h and 
then day 2–5 daily) in human treatment with uncomplicated and severe/complicated malaria on day 1*.
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Figure 1. 
Standard parasite clearance curve in different stages (lag phase, clearance phase, dormant and terminal phase) 
and synchronicity of parasite development under antiparasitic drug received at 0 h (top chart). The mean 
parasite clearance curves (bottom chart) of AS (solid line) at single intravenous 120 mg and oral 100 mg at 
8 h, then oral 750 mg mefloquine at 24 h [26, 27]; oral AS (dashed line) at 100 mg first day and 50 mg b.i.d 
2–5 days orally [22, 28, 29]; oral DHA (dot and dashed line) at 200 mg first day and 100 mg 2–5 days orally 
[30, 31]; oral QHS (solid line) at 500 mg first day, 250 mg b.i.d 2–5 and 500 mg last day orally [19–21, 29]; 
intramuscular AM (dashed line) at 3.2 mg/kg first day and 1.6 mg/kg 2–5 days intramuscularly [35, 36]; and 
intramuscular AE (dot line) of 4.8 mg/kg at 0 h and 1.6 mg/kg at 6 and then 2–5 days intramuscularly [38, 39], 
in malaria patients (bottom chart) (Table 1). The parasitemia at 0 h was set as 100% of parasitemia.
following administration presents as a lag phase. This lag phase is then followed by 
a sharp drop in parasite burden (representing the clearance phase), which is then 
followed by a slow decrease to very low parasitemia levels. Subsequent phases of this 
process are usually under the limits of microscopic detection of both the dormant and 
terminal phases (Figure 1, top). The artemisinins affect this profile in multiple ways. 
First, they prevent the continuation of merogony at later stages of parasite develop-
ment as compared to quinine or mefloquine. This stops the occasional alarming sharp 
rise in parasitemia immediately following treatment described earlier (lag phase). 
5Pharmacokinetic and Pharmacodynamic Profiles of Rapid- and Slow-Acting Antimalarial Drugs
DOI: http://dx.doi.org/10.5772/intechopen.83505
Second, the drop in parasite load is accelerated. This is explained by enhanced clear-
ance of erythrocytes infected with ring forms (clearance phase) [24]. Rapid termina-
tion, surviving and stage unaffected parasites display very low levels of dormancy 
[25], which is the basis of the recrudescence (dormant and terminal phase). Different 
artemisinins with varied methods of delivery show different parasitemia-time 
profiles (Figure 1, bottom). Although the PK/PD publication record is very limited, 
the possible PK and PD evaluations for individual drugs with the same regimens 
in monotherapy for human-malaria are described below; and the PK data of five 
artemisinin drugs (AS, DHA, QHS, AM, and AE) corresponding with parasitological 
consequences in malaria patients are shown in Table 1, Figures 1 and 2.
2.1 Intravenous-artesunate (IV-AS)
PK/PD profiles in humans were studied following AS intravenous administra-
tion at doses of 120 mg/person on the first day at 0 h followed by oral 100 mg at 8 h 
(Figure 2, top left). A mean peak level (Cmax) of 11.343 ng/ml was displayed for 
IV-AS, which rapidly cleared with an elimination half-life of 0.05 h. The Cmax of 
DHA, the primary metabolite of AS, was 2646 ng/ml with an elimination half-life 
Figure 2. 
Pharmacokinetic/pharmacodynamic profiles are in plasma following intravenous-artesunate and oral 
artesunate (AS, with DHA measurement) [22, 26–29], oral dihydroartemisinin (DHA) [30, 31], oral 
artemisinin (QHS) [19–21, 29], intramuscular artemether (AM) [35, 36], and arteether (AE) [38, 39] with 
various regimens measured by HPLC-ECD or LC-MS (solid markers) and computer-fitted curves (solid line) 
are from malaria human trials. Relative PK/PD parameters are given in Table 1, and the parasitemia was 
counted 100% at zero while the first dosing time.
Malaria
6
of 0.67 h (Table 1). The mean AUC for DHA was 2378 ng h/ml, which is 2 times 
higher than that of the parent compound, AS, (AUC of 1146 ng h/ml) [26, 27].
In this trial, the lag phase for the parasitemia curve was estimated as 1.92 h 
(Table 1), which was the shortest as compared to oral AS and 4 other drugs 
(Figure 1, bottom), indicating that the IV-AS injection very efficiently kills 
parasites, with a mean time of 3.18 h for clearance of half the parasitemia (PC50), 
which is the lowest PC50 and has the lowest area under inhibitory curve (AUIC) 
at 397.3% h/μl in this evaluation (Table 1). After modeling, an Emax of 0.00111% 
parasitemia was estimated for IV-AS therapy on the first day. The Emax was the 
principal pharmacodynamic parameter determining maximum antimalarial 
effects for the artemisinins, as it displayed a sharp concentration-effect rela-
tionships. This relationship may be due to the time that blood concentrations 
exceeded the minimum parasiticidal concentration (MPC), as opposed to being 
driven by either Cmax or AUC [25]. For the data presented in this chapter, the MPC 
was the lowest after administration of100 mg per patient of IV-AS, with parasit-
emia remaining in blood (0.0011%) as compared to the other four artemisinin 
derivatives addressed (Table 1).
2.2 Oral artesunate (AS)
PK/PD profiles in plasma were studied following oral AS administration of 
100 mg/person tablets on first day, followed by 50 mg twice daily for 2–6 days 
(Figure 2, top right). The mean peak plasma concentration of DHA was measured 
at 1052 ng/ml, with an elimination half-life of 0.75 h (Table 1). Also, the AS con-
centration declined day-over-day for the 5-day duration of dosing [22]. Mean AUC 
of DHA was calculated to be 1334 ng h/ml, 6.4 times higher than that of the parent 
compound (AUC of 210 ng h/ml), AS [28].
With the same oral dose regimen of AS, the time of lag phase in the parasitemia 
curve was only 2.81 h, shorter when compared to the four other artemisinins, with 
a range of 4.03–8.89 h (Figure 1, bottom) but longer than that of IV-AS (1.92 h), 
indicating that the effect of AS tablets was very efficient with a 0.36 h absorption 
half-life and a Cmax of 1052 ng/ml [29]. Similarly, rapid parasite clearance with a 
mean time of 8.48 h for clearance of half the parasite load (PC50), the lowest PC50 of 
the four drugs and the lowest AUIC with 921.2% h/μl (Table 1). After modeling, an 
Emax of 0.0016% parasitemia was calculated for oral treatment with AS on the first 
day. For the data presented here, the MPC was the lowest, with parasitemia remain-
ing in blood after dosing with 100 mg of AS per patient as compared to other four 
artemisinin derivatives (Table 1).
2.3 Oral dihydroartemisinin (DHA)
Profiles of PK/PD in plasma following administration of 200 mg/person in tablets 
DHA on day 1 followed by 100 mg at day 2–5 are shown in Figure 2 (middle left). 
After 200 mg of DHA, the mean peak plasma concentration of DHA was 437 ng/
ml with an elimination half-life of 0.85 h. The mean AUC of DHA was calculated to 
be 1329 ng h/ml. With the 200 mg oral dose regimen, the time of lag phase in the 
parasitemia curve was 4.03 h, longer than that of oral (1.92 h) and IV-AS (2.81 h) but 
still shorter than either QHS (5.76 h), AM (7.26 h), or AE (8.89 h), indicating that 
the rapid clearance effect of DHA tablets was inferior to AS, but superior to QHS, 
AM, and AE regimens. Additionally, this rapid parasite clearance resulted in a mean 
time of 10.05 h of PC50 and an AUIC of 1167.9% h/μl (Table 1, Figure 1, bottom). 
After the first day, modeling estimates of the Emax were 0.213% parasitemia for oral 
DHA treatment. For the data presented here, after 200 mg per patient of DHA, high 
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MPC remained in the blood as compared to the other three artemisinin derivatives 
(Table 1). Absorption of DHA tablets, with 0.67 h half-life, was 50% slower than 
that of AS (0.36 h) in this trial as well, indicating that the relatively slow reduction of 
parasitemia may have resulted from the slow absorption [30, 31].
As compared to oral AS, the AUCs of treatments with either AS or DHA (in 
oral form) the same, with only Cmax of oral AS differing, and was two times higher 
than oral DHA treatment, suggesting that this high peak concentration (Cmax) 
may be causally related to the decrease of parasitemia in patients [30, 31]. DHA 
appeared to have very low bioavailability (<50%). If calculated with an equal dose 
level, the Cmax and AUCDHA estimated from AS treatment were four- and twofolds, 
respectively, higher than the DHA dosage regimen. Our data demonstrate that the 
DHA tablet (Cotexin) in beagle dogs had only 24.4% absolute bioavailability [32]. 
In malaria patients, rebound parasites (3%) on day 3 and one-fourth recrudescence 
rate (24%) were found in subjects treated with DHA tablets in clinical work [30]. 
The 3% of rebound parasites were only found in DHA oral treatment in this com-
parison (Figure 2).
2.4 Oral artemisinin (QHS)
PK/PD evaluation in plasma following artemisinin (QHS) oral administration of 
500 mg/person on the first day followed by 250 mg twice daily for 4 days and then 
another 500 mg on 6th day is seen in Figure 2 (middle right). After 500 mg of QHS 
by oral dosing, the mean peak plasma concentration of QHS was reached at 588 ng/
ml and then declined with an elimination half-life calculated at 2.4 h. The mean 
AUC of QHS was estimated at 2601 ng h/ml, which was a comparatively high AUC 
due to the oral dose taken. With the 500 mg oral dosage regimen, the lag time in the 
parasitemia curve was 5.76 h, which was longer than oral and IV-AS (1.92–2.81 h) 
and DHA (4.03 h) but was better than AM and AE in trials (Figure 1, bottom). 
This indicates that the rapid effect of QHS capsules was not as good as oral AS and 
DHA even given at three- to sixfold higher doses [19–21, 29]. The patients treated 
with oral QHS showed 13.95 h of PC50 and the 1464.4% h/μl of AUIC (Table 1). The 
absorption of QHS capsules with a 1.21 h half-life was slower than the absorptions 
of AS and DHA drugs, suggesting that the slow reduction of parasitemia may have 
resulted from slow absorption and lower antimalarial potency. Compared with oral 
AS and DHA study, oral QHS appeared to have very low bioavailability of 30% [33] 
and low antimalarial potency with cultured P. falciparum [34].
2.5 Intramuscular artemether (AM)
PK and PD profiles in plasma following AM intramuscular administration in 
sesame oil of 3.2 mg/kg on day 1 and then 1.6 mg/kg daily on day 2–5 can be seen in 
Figure 2 (bottom, left). The mean peak plasma concentration was reached at 74.9 ng/
ml and then declined with an elimination half-life calculated at 7.83 h (Table 1), indi-
cating that this formulation had the lowest peak of drug concentration when com-
pared to the other four artemisinin drugs. A mean AUC was estimated at 1230 ng h/ml 
[35, 36]. At the same dosage regimen, the time of lag phase in the parasitemia curve 
was 7.26 h, which was the second longest lag time compared with the other three 
drugs except for AE, indicating that the effect of the AM intramuscular formulation 
had a very low and prolonged absorption from muscle injection sites [37].
Parasitemia counts early after dosing did not decrease due to the low peak 
concentration of AM, but increased markedly to 110% at 4 h (parasitemia was set 
at 100% of the zero dosing time). This observation may explain why the lag time 
was longer at 7.26 h with no parasite decrease after injection. Similarly, there was 
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very slow clearance of parasites producing a mean PC50 time of 15.6 h (Figure 1, 
bottom), which was also the longest PC50 time compared to the other three drugs 
except AE (Table 1). The AUIC of 1613.4% h/μl also revealed that this drug given 
as an intramuscular regimen was not efficacious in reducing parasitemia [35]. 
Although intramuscular AM was not fast enough to kill parasites in patients, 
the long-lasting exposure level of AM (7.83 h elimination half-life) could reduce 
parasitemia at an acceptable rate. Computer modeling estimated the Emax at 0.003% 
parasitemia in this clinical trial. The MPC (Emax) was only a little more than oral AS 
in the first-day modeling, but much less than oral DHA, oral QHS, and intramuscu-
lar AE (Table 1).
2.6 Intramuscular arteether (AE)
PK and PD profiles in plasma following AE intramuscular administration in 
sesame oil of 4.8 mg/kg at 0 h and 1.6 mg/kg at 6 h on day 1 and then daily 1.6 mg 
from day 2–5 are illustrated in Figure 2 (bottom, right). The mean peak plasma con-
centration was reached at 110.1 ng/ml and then declined with an elimination half-life 
calculated at 22.7 h (Table 1), indicating that this formulation has a low peak of drug 
concentration when compared to AS, DHA, and QHS. Mean AUC was estimated 
at 4702 ng h/ml [38]. At the same dosage, the lag time in the parasitemia curve was 
8.89 h, which was the longest lag time and the highest AUC value compared with the 
other four drugs, indicating that the effect of the AE intramuscular formulation had 
a very low and prolonged absorption from muscle injection sites [37].
Parasitemia counts early after dosing did not decrease due to the low peak con-
centration of AE, but increased to 108% at 6 h (100% parasitemia set at 0 h of the 
first dosing time). As with AM, this increase may be the reason why the lag time is 
longer at 8.89 h with no parasite killing after injection. Similarly, a very slow parasite 
clearance was produced at mean PC50 time of 19.68 h, which was the longest PC50 
time compared to the other four drugs (Table 1). The highest AUIC of 2463.5% h/μl 
revealed that the drug with the intramuscular regimen was not efficacious in reduc-
ing parasitemia [35, 39]. Intramuscular AE was neither able to exterminate parasites 
rapidly, nor to reduce parasitemia much in patients revealing it to be an inferior 
antimalarial agent when compared to the other four drugs (Figure 1, bottom). The 
computer modeling estimated the Emax at 0.55% parasitemia in this clinical trial. In 
spite of two doses on day 1 (4.8 mg/kg at 0 h and 1.6 mg/kg at 6 h), the Emax was still 
the highest value compared to other the four artemisinins (Table 1).
3.  Efficacy and potency of artemisinins depending on drug peak 
concentration
Intravenous and oral AS are the fastest killers of parasites in human malaria 
treatments out of the five artemisinins, indicating that AS is a superior antimalarial 
agent in performance of PK/PD. IV-AS provides the highest peak concentration 
and a very short exposure time, while oral AS can also provide high peak levels and 
similar short exposure times. The data suggest that the higher peak level has a major 
role in eliminating parasites rapidly and the short exposure time contributes to the 
avoidance of fatal neurotoxicity [40, 41] as well as prevention of resistance [42].
Although DHA has similar efficacy to AS in vitro [34], the agent does not have as 
rapid effect as IV-AS or oral AS, even with twofold higher dosing. The explanations 
include lower bioavailability [43, 44], which results in a slower absorption phase, 
and a long lag time which has an effect on activity. However, we believe the principal 
reason is due to the lower peak concentration observed when compared to oral AS.
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Oral artemisinin (QHS) does not compete well in this PK/PD comparison with its 
relatively low potency against cultured P. falciparum [34]. Although high oral doses 
(three- to sixfolds higher than oral DHA and AS, Table 1) produced higher plasma 
concentrations (2601 ng h/ml of AUC) and high peak concentrations (588 ng/ml), the 
relatively low potency [34] and bioavailability [33] significantly limited the efficacy.
Intramuscular AM or AE consistently displays low efficacy and slow parasite 
killing. Due to the sesame oil formulation, AM and AE have a very low and pro-
longed absorption from muscle injection sites [37]. Initially, parasitemia counts 
after dosing do not decrease due to the low and delayed peak concentrations 
(75–110 ng/ml) of AM and AE. This may be the main reason for slow elimination 
of parasites as the observed lag times of 7.2–8.9 h are the longest of the drugs. 
Subsequently, they have the slowest clearance rates, with mean PC50 times of 
15.63–19.68 h, potentially resulting in inadmissible failures in some of the AE trials 
(Table 1) [38]. Although drug exposure times of AM and AE are comparatively 
longer than AS, DHA, and QHS, this long exposure apparently did not improve 
efficacy. Instead, it seems to induce neurotoxicity [41]; therefore, this formulation 
should not be encouraged for clinical use to treat acute and severe malaria as safer 
agents are available.
PK/PD evaluations demonstrate that the rapid efficacy of the artemisinins is 
principally due to the drug peak concentration (Cmax). This further indicates that 
AS has superior PK/PD following either oral or intravenous administration. Other 
pharmacokinetic parameters, such as drug exposure level (AUC) and drug exposure 
time (half-life), tend to be of minor importance for efficacy [45]. Most clinical 
observations demonstrate that the fast pharmacodynamic properties of these drugs 
have been largely addressed with pharmacokinetic findings [38, 45, 46]. Further, 
low drug exposure of artemisinins may be a cause for observed treatment failures 
[37, 47, 48]. These studies showed that using a low dose regimen may not provide 
enough drug exposure to kill the parasites in these patients [49]. In contrast, the 
clinical cure indicated that the intravenous formulations, like AS injection, are very 
important in the rapid treatment of malaria with high observed peak concentra-
tions (Cmax), especially in severe and complicated malaria [26, 27].
Evidence shows that higher plasma concentrations (Cmax and AUC), especially 
peak concentrations (Cmax), greatly enhance the efficacy and clinical therapeutic 
potentials of the artemisinins. As previously discussed, the severity of the possible 
complications for P. falciparum malaria constitutes a serious medical emergency, 
and appropriate treatment should be initiated if infection is suspected. Appropriate 
treatment requires enough high-dose regimens and should be given to provide 
successful therapeutic efficacy for malaria patients, as it is known that 84% of all 
malaria related deaths occur within 24 h of hospital admission in African children 
[50]. As such, first exposure concentrations of artemisinin drugs are critical in the 
clinical setting.
4.  PK/PD evaluation of artemisinin-based combination therapies 
(ACTs)
In order to avoid a high recrudescence of the monotherapy of artemisinins and 
to delay or prevent emergence of artemisinin resistance, WHO recommends the use 
of combination therapies for the treatment of uncomplicated P. falciparum malaria. 
Artemisinin derivatives rapidly decrease the parasite biomass, while the presence of 
partner antimalarial drugs with a different and slow-acting mechanism reduces the 
probability of high recrudescence. These therapies include one artemisinin deriva-
tive plus a partner, slow-acting, antimalarial drug with a longer half-life [51, 52]. 
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WHO encourages the development of fixed-dose combination (FDC) versions of 
ACTs, versus coblistered tablets that can be misused to facilitate administration of 
artemisinin as monotherapy.
Two ACT combinations, artesunate-sulfadoxine/pyrimethamine (AS-SP) and 
artesunate-amodiaquine (AS-AQ ), are used in areas where parasites are suscep-
tible to these drugs. In areas where resistance to sulfonamide-pyrimethamine, 
chloroquine, and amodiaquine is prevalent, other artemisinin combinations are 
used such as artemether-lumefantrine (AL) or artesunate-mefloquine (AS-MQ ). 
More recently, dihydroartemisinin-piperaquine (DP) is a promising ACT option 
that exhibits an excellent efficacy and safety profile and is currently the first-line 
therapy for uncomplicated malaria in Asia. Currently, artemisinins have been intro-
duced to the market combined with other slow-acting drugs to create fixed-dose 
ACTs containing amodiaquine, mefloquine, and piperaquine [53].
Artemisinin-resistant falciparum malaria has developed on the border 
between Thailand and Cambodia. The development of artemisinin resistance is 
likely a consequence of patient treatment with artemisinin monotherapy with 
substandard, counterfeit, or adulterated drugs for over 40 years. This artemis-
inin resistance phenomenon is characterized clinically by much slower parasite 
clearance rates after artemisinin treatment [54]. This artemisinin resistance, 
defined by a delayed parasite clearance time, has been associated with several 
genetic mutations.
One hypothesis to explain this phenomenon is delayed parasite clearance derived 
from a stage-specific decrease in artemisinin sensitivity against circulating young 
asexual ring-stage parasites. Another hypothesis to explain this phenomenon is 
dormancy of ring-stage parasites in vivo, which would render them resistant to 
artemisinin treatment. A related hypothesis is that reduced sensitivity to treatment 
with artemisinins renders the ACT partner drug vulnerable to development of 
resistance. This very ominous development accompanied with the development of 
resistance over time in Asia to all of the partner drugs used for ACTs suggests that 
all of the current ACT regimens would be predicted to fail in Southeast Asia. This 
phenomenon will lead to malaria recurrence after treatment, and decreased efficacy 
of artemisinin-based treatment of severe malaria. To assess this question further 
concerning AS-MQ efficacy, a clinical trial was conducted on the Thai-Cambodian 
border using this combination to treat 151 subjects infected with uncomplicated 
falciparum malaria. Patients were followed over a 42 day period or until recurrent 
parasitemia was observed. The PCR-corrected treatment failure rate at 28 days was 
13.1%, and the treatment failure rate at 42 days after treatment was 18.8%. These 
treatment failures were associated with longer parasite clearance times, increased 
pfmdr1 copy number, increased initial parasitemia, and elevated mefloquine IC50 
values. These data demonstrate the combined effects of artesunate resistance and 
mefloquine resistance in this region [55].
Similar to other drug resistance phenotypes, this resistance can best be under-
stood based on its mechanism of action. More recently, it was demonstrated that 
artemisinin attacks multiple parasitic targets, suggesting that mutations in drug 
targets are unlikely to cause high-level artemisinin resistance. These findings will 
help us to better understand the mechanisms of artemisinin resistance and suggest 
that how can we continue to use ACTs [51].
There is a very large body of evidence to support the hypothesis that ACTs 
provide the best possible treatment available today for uncomplicated multidrug-
resistant falciparum malaria. ACTs provide rapid treatment responses that are well 
tolerated, provide excellent cure rates with 3-day treatment regimens, provide 
reductions in gametocyte carriage, and decrease drug resistance by providing 
protection for combination partner drugs.
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Clinical trials in 10 investigational sites in 7 African countries (Burkina Faso, 
Nigeria, Gabon, Zambia, Uganda, Rwanda, and Mozambique) were performed. About 
4116 African children under 5 years of age with uncomplicated P. falciparum malaria 
were treated with four ACTs: 1226 with AL, 1002 with AS-AQ , 413 with chlorprogua-
nil-dapsone-artesunate (CDA), and 1475 with DP. The PCR-corrected cure rate on day 
63 showed no differences between DP, AL, and AS-AQ , while these three ACTs were 
statistically superior in comparison with CDA. The PCR-uncorrected cure rate at day 
63 indicated that DP was statistically superior to AL, AS-AQ , and CDA [56].
In addition, the efficacy of the Eurartesim® formulation of DP in Thailand, 
Laos, and India was compared with that of AS-MQ for the treatment of patients 
aged 3 months to 65 years with uncomplicated P. falciparum malaria in a noninfe-
riority trial conducted in Asia. DP was shown to be a highly efficacious drug for 
the treatment of uncomplicated P. falciparum malaria in areas where multidrug 
parasites are prevalent [57].
Several additional trials compared the efficacy of the Artekin® formulation of 
DP versus AS-MQ in patients with uncomplicated P. falciparum malaria. Most of the 
trials were conducted in Asia with one trial conducted in Peru, and the majority of 
trials included both pediatric and adult patients. DP was shown to be highly effec-
tive for the treatment of uncomplicated P. falciparum malaria [58].
Antimalarial drug resistance is now well established in both P. falciparum and 
P. vivax. In southern Papua, Indonesia, where both strains of Plasmodia coexist, a 
series of studies were conducted to optimize treatment strategies. A randomized 
trial compared the efficacy and safety of DP with AS-AQ. Of the 334 patients in the 
evaluable patient population, 185 were infected with P. falciparum, 80 were infected 
with P. vivax, and 69 were infected with both species. DP was both more efficacious 
and better tolerated than AS-AQ when used to treat multidrug-resistant P. falciparum 
and P. vivax infections. The prolonged therapeutic effects of piperaquine appeared to 
delay the time to P. falciparum reinfection, decrease the rate of recurrence of P. vivax 
infection, and reduce the risks of both gametocyte carriage and anemia [59].
Other studies have also shown that DP has excellent efficacy for the treatment of 
uncomplicated malaria. The results showed that DP was superior to AL and AS-AQ 
for reducing the risk of recurrent parasitemia and recrudescence [60]. DP has con-
sistently been shown to be well tolerated, safe, and efficacious in adults and children 
in Asia, Africa, and South America, both in children and in adults with uncompli-
cated malaria due to P. falciparum, P. vivax, or mixed infections with significantly 
less nausea, vomiting, and dizziness than AS-MQ [58, 61]. DP was also better toler-
ated, with no clinically significant cardiovascular or metabolic effects [58].
Recently, nine trials compared the efficacy of Eurartesim®, Duocotecxin®, or 
Artekin® formulations of DP with that of AL in patients with uncomplicated  
P. falciparum malaria. Most of these trials were conducted in Africa, with one 
trial conducted in Cambodia. These additional trials demonstrated the efficacy 
of DP for the treatment of uncomplicated P. falciparum malaria. DP was shown 
to be superior to AL with respect to other endpoints, including fever and parasite 
clearance times, reinfection rates, and gametocyte carriage rates [58].
The conclusions of those studies were that DP was shown to be a safe, well toler-
ated, and highly effective treatment of P. falciparum malaria in Asia and Africa, but 
the effect on gametocyte carriage was inferior to that of AS-MQ [62].
5. Therapeutic effects of ACTs depending on the half-life of partner drug
Concerning therapeutic benefits, combination therapy minimizes the risk 
of emergence and spread of parasites resistant to either agent. Preventing the 
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development of artemisinin resistance is of vital importance given the crucial role 
artemisinin derivatives play in malaria control and treatment programs. Artesunate 
resistance has already emerged in western Cambodia [1, 63]; however, ACTs are still 
capable of achieving cure rates exceeding 90%. Since 2001, WHO guidelines have 
recommended the use of ACTs to include DP, AL, AS-MQ , AS-AQ , and AS-SP to 
treat patients with uncomplicated P. falciparum malaria. Among those ACTs, DP 
represents a new and extremely promising fixed-dose combination. Several clinical 
trials have repeatedly shown that DP is a safe and highly efficacious therapy against 
uncomplicated P. falciparum and the asexual stages of P. vivax malaria. The risk of 
recurrent infections was significantly lower for DP, followed by AS-AQ and then 
AL, supporting the recent WHO recommendation to consider DP as a valid option 
for the treatment of uncomplicated P. falciparum malaria [64].
These therapies include one artemisinin derivative plus a partner compound, 
slow-acting, antimalarial drug with a longer half-life [51, 52]. The cumulative risk 
of parasitological failure was greater in studies of patients treated with AL, AS-MQ , 
and AS-SP than in patients treated with DP, reflecting the very long half-life of 
piperaquine. The long half-life of piperaquine is expected to have a major impact 
in improving the health-care systems of countries in P. falciparum malaria endemic 
areas (Table 2). Piperaquine has a large apparent volume of distribution (greater 
than 500 l/kg) and a terminal elimination half-life estimated around 5 weeks. With 
increasing sensitivity of assay techniques, the true terminal half-life is probably 
similar to that of chloroquine, 1–2 months. The oral bioavailability of piperaquine 
increases with coadministration with fat [58, 64–67].
In addition, the superior efficacy of DP for the treatment of P. vivax in malaria 
endemic areas versus chloroquine or other ACTs may reflect some measures of 
chloroquine resistance in areas where trials were conducted or comparison with 
one of the longer acting ACTs. Of the ACTs, DP has the longest half-life and as such 
was shown to be highly efficacious at preventing P. vivax relapses for up to 56 days 
following treatment. In a separate study, AS-MQ also provided protection against 
P. vivax parasitemia for up to 63 days. The shorter half-life combinations such as 
AL, although equally effective at rapidly reducing parasite biomass, were shown to 
provide comparatively little protection against early relapse [64–67]. Accordingly, 
the DP combination demonstrably has superior PK/PD qualities compared to all 
other ACTs recommended by WHO.
Antimalarials Half-life of 
artemisinin 
derivative
Half-life of partner 
drug per full adult 
course (US$)
Regions currently in use 
purchase cost per course (US$)
Artemether-lumefantrine
Artesunate-mefloquine
Artesunate-amodiaquine*
Dihydroartemisinin-
piperaquine
Artesunate-pyronaridine
Chloroquine1
Sulfadoxine-pyrimethamine
~3 h
<1 h
<1 h
45 min
<1 h
NA
NA
4–5 days
14–21 days
9–18 days
~5 weeks
16 days
1–2 months
~4 days (S) or
~8 days (P)
Africa, EM, SE Asia, WP and SA
Africa, SE Asia, WP and SA
Africa and EM
Africa, SE Asia
NA
Africa, EM, SE Asia, WP and SA
Africa, EM (IPT in Africa, 
EM and WP)
*This refers to the t1/2 of the active metabolite monodesethylamodiaquine; the t1/2 of amodiaquine is ~3 h
1These former first-line antimalarials are included as a reference. EM, eastern Mediterranean; IPT, intermittent 
preventive treatment; NA, not applicable; P, pyrimethamine; S, sulfadoxine; SA, South America; SE Asia, Southeast 
Asia; t1/2, half-life; WP, Western Pacific.
Table 2. 
Plasma half-lives of the partner drugs used in artemisinin-based combination therapies (ACTs) [58, 64–67].
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6. Conclusion
Artemisinins have been used clinically in the treatment of malaria for over 
40 years, during which time their mechanism of action and pharmacokinetic 
properties have been elucidated. Empirical judgments concerning efficacy and 
optimal administration have been influenced by their impressive parasite clearance 
kinetics, which are superior to many commonly used alternatives. Among the five 
artemisinins in current use, the PK/PD profiles of AS are the best.
This report has also discussed the fact that the rapid efficacy of artemisinins is 
principally driven by peak concentration (Cmax) from the first drug exposure. Other 
factors in the pharmacokinetic parameters, such as drug exposure level (AUC) and 
drug exposure time (half-life), appear to be of lesser importance. By the fundamen-
tal and reliable measures of efficacy in cure and mortality rates for uncomplicated 
and severe malaria, it is demonstrated that current artemisinins (AS, AM, and 
DHA), performing in roles as ACT or monotherapy, provide a clear-cut advantage 
over other antimalarials in some geographical locations. The most recent advances 
in the decrease of the mortality (34.7%) were shown with the use of IV-AS, as 
compared to IV quinine.
Although the artemisinins are poorly efficacious at achieving 100% cure in 
malaria when used as monotherapies, this shortage has been overcome using oral 
ACTs and IV-AS sequentially with a slower acting partner drug such as mefloquine 
or piperaquine. Previous arguments for the long-term benefits of combination and 
sequential therapies for preventing resistance and recrudescence still stand. The rapid 
action and subsequent decrease in mortality show that the artemisinins have a great 
advantage over other antimalarials when used as ACTs for uncomplicated malaria and 
in sequential therapy with AS injection in cases of severe and complicated malaria.
As a result of the long half-life of oral piperaquine, DP has excellent PK/PD 
potential when compared to all other ACTs. Importantly, WHO guidelines for the 
treatment of malaria expanded to include DP as an ACT option for the “first-line 
treatment of uncomplicated P. falciparum malaria worldwide” [53]. This was catego-
rized as a “Strong Recommendation” and was added due to “High Quality Evidence.”
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